202 related articles for article (PubMed ID: 29440633)
41. miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS.
Neu J; Dziunycz PJ; Dzung A; Lefort K; Falke M; Denzler R; Freiberger SN; Iotzova-Weiss G; Kuzmanov A; Levesque MP; Dotto GP; Hofbauer GFL
PLoS One; 2017; 12(9):e0185028. PubMed ID: 28931048
[TBL] [Abstract][Full Text] [Related]
42. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer.
Zhang Z; Yang Y; Zhang X
Life Sci; 2017 Nov; 188():163-171. PubMed ID: 28882645
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.
Guo J; Feng Z; Huang Z; Wang H; Lu W
Mol Cells; 2014 Sep; 37(9):664-71. PubMed ID: 25234467
[TBL] [Abstract][Full Text] [Related]
44. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA profile of tumorigenic cells during carcinogenesis of lung adenocarcinoma.
Zhao ZG; Jin JY; Zhang AM; Zhang LP; Wang XX; Sun JG; Chen ZT
J Cell Biochem; 2015 Mar; 116(3):458-66. PubMed ID: 25359683
[TBL] [Abstract][Full Text] [Related]
46. NKX2-1 expression as a prognostic marker in early-stage non-small-cell lung cancer.
Moisés J; Navarro A; Santasusagna S; Viñolas N; Molins L; Ramirez J; Osorio J; Saco A; Castellano JJ; Muñoz C; Morales S; Monzó M; Marrades RM
BMC Pulm Med; 2017 Dec; 17(1):197. PubMed ID: 29237428
[TBL] [Abstract][Full Text] [Related]
47. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status.
Dacic S; Kelly L; Shuai Y; Nikiforova MN
Mod Pathol; 2010 Dec; 23(12):1577-82. PubMed ID: 20818338
[TBL] [Abstract][Full Text] [Related]
48. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
[TBL] [Abstract][Full Text] [Related]
49. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
50. Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer.
Yang K; Zhang W; Zhong L; Xiao Y; Sahoo S; Fassan M; Zeng K; Magee P; Garofalo M; Shi L
Cell Death Differ; 2023 Jun; 30(6):1533-1549. PubMed ID: 37041291
[TBL] [Abstract][Full Text] [Related]
51. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
[TBL] [Abstract][Full Text] [Related]
52. Ablation of insulin receptor substrates 1 and 2 suppresses
Xu H; Lee MS; Tsai PY; Adler AS; Curry NL; Challa S; Freinkman E; Hitchcock DS; Copps KD; White MF; Bronson RT; Marcotrigiano M; Wu Y; Clish CB; Kalaany NY
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4228-4233. PubMed ID: 29610318
[TBL] [Abstract][Full Text] [Related]
53. miR-212-5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells.
Chen FF; Sun N; Wang Y; Xi HY; Yang Y; Yu BZ; Li XJ
J Cell Physiol; 2020 Oct; 235(10):7273-7282. PubMed ID: 32039486
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-422a functions as a tumor suppressor in non-small cell lung cancer through SULF2-mediated TGF-β/SMAD signaling pathway.
Li WQ; Zhang JP; Wang YY; Li XZ; Sun L
Cell Cycle; 2019 Aug; 18(15):1727-1744. PubMed ID: 31204561
[TBL] [Abstract][Full Text] [Related]
56. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
57. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Kharbanda A; Walter DM; Gudiel AA; Schek N; Feldser DM; Witze ES
Sci Signal; 2020 Mar; 13(621):. PubMed ID: 32127496
[TBL] [Abstract][Full Text] [Related]
58. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
59. MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer.
Edmonds MD; Boyd KL; Moyo T; Mitra R; Duszynski R; Arrate MP; Chen X; Zhao Z; Blackwell TS; Andl T; Eischen CM
J Clin Invest; 2016 Jan; 126(1):349-64. PubMed ID: 26657862
[TBL] [Abstract][Full Text] [Related]
60. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
